Like many insurers, UnitedHealthcare and Optum are dealing with a surge in digital solutions, according to Dr. Debra Nussbaum, senior director of behavioral health at Optum. And they’re trying ...
When Johnson & Johnson backed down from its proposal to modify the way it supplies certain drugs under the 340B statute, it hinted litigation could be its next step to effect changes that address ...
There is no single remedy to fix extreme healthcare cost challenges. Healthcare inflation cuts across multiple factors. So employers need multiple ways to reverse these trends in 2025. Join us for ...
GLP-1 is expected to grow to a $71 billion industry by 2031. GLP-1 medications are fueled by the 66% of Americans who are classified as overweight or obese. No matter what metric, GLP-1 ...
Former President Donald Trump’s return to the White House is certain to bring about changes across many facets of the healthcare sector — including reproductive care, federal insurance ...
Fort Health, an integrated behavioral health company, has secured $5.5 million, it announced Tuesday. It will use these funds to bring mental health services into more pediatricians’ offices in ...
The radioligand therapy (RLT) space is entering a new era, as demonstrated by Eli Lilly’s recent $4.5 billion investment in a new research and manufacturing infrastructure. Pharmaceutical ...
Neurogene Gene Therapy Shows Signs of Efficacy in Small Study, But an Adverse Event Spooks Investors
A Neurogene gene therapy in development for the rare neurodevelopmental disorder Rett syndrome has encouraging early data in a small group of patients, an interim readout that comes a week after a ...
Maternal mental health conditions are among the most prevalent complications during pregnancy and the postpartum period. There is also a significant economic burden associated with maternal mental ...
Tech giant Microsoft has pursued dozens of partnerships with health systems over the past few years, with these focusing mainly on fine-tuning AI models to better serve busy clinicians. Last month ...
From L-R: Betty Pio, partner at Kearney; Dr. Rekha Kumar, chief medical officer at Found and practicing endocrinologist at New York-Presbyterian; Sheila Shah, managing director, L.E.K. Consulting ...
An AbbVie schizophrenia drug acquired as part of a multi-billion dollar deal has failed two mid-stage studies, dealing a setback to the company’s plans to compete with a Bristol Myers Squibb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback